Lisanti Capital Growth LLC Grows Stock Holdings in TransMedics Group, Inc. $TMDX

Lisanti Capital Growth LLC lifted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 62.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,901 shares of the company’s stock after buying an additional 21,771 shares during the period. TransMedics Group makes up about 1.6% of Lisanti Capital Growth LLC’s portfolio, making the stock its 15th largest position. Lisanti Capital Growth LLC owned approximately 0.17% of TransMedics Group worth $6,384,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in TransMedics Group by 1.4% in the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after purchasing an additional 11,241 shares during the last quarter. Marshall Wace LLP boosted its position in shares of TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Zevenbergen Capital Investments LLC grew its stake in TransMedics Group by 112.7% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after buying an additional 136,995 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in TransMedics Group by 5.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 221,276 shares of the company’s stock valued at $29,653,000 after buying an additional 11,599 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. This trade represents a 5.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. The trade was a 17.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 8,920 shares of company stock worth $1,257,310 in the last three months. Company insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group boosted their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Finally, Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Price Performance

Shares of TMDX opened at $133.98 on Friday. The business’s 50-day moving average is $134.30 and its two-hundred day moving average is $123.60. The company has a market capitalization of $4.58 billion, a P/E ratio of 54.24 and a beta of 2.03. TransMedics Group, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period last year, the company earned $0.12 earnings per share. TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.